Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
Foghorn Therapeutics (Nasdaq: FHTX), a clinical-stage biotechnology company focused on correcting abnormal gene expression, announced its participation in two upcoming investor conferences in February and March 2025.
The company will join the B. Riley Securities Precision Oncology and Radiopharma Conference on February 28, 2025, where President and CEO Adrian Gottschalk will participate in a Synthetic Lethality Panel at 9 a.m. EST in New York.
Additionally, Foghorn will present at the TD Cowen 45th Annual Health Care Conference on March 3, 2025, at 2:30 p.m. EST in Boston, with management also conducting virtual one-on-one meetings that day.
Webcasts of the presentations will be available under the "Events & Presentations" section of Foghorn's website for 90 days. The company's Gene Traffic Control® platform focuses initially on oncology with potential applications across a wider spectrum of diseases.
Foghorn Therapeutics (Nasdaq: FHTX), una società biotecnologica in fase clinica focalizzata sulla correzione dell'espressione genica anomala, ha annunciato la sua partecipazione a due importanti conferenze per investitori in programma a febbraio e marzo 2025.
La società parteciperà alla B. Riley Securities Precision Oncology and Radiopharma Conference il 28 febbraio 2025, dove il Presidente e CEO Adrian Gottschalk parteciperà a un panel sulla Lethalità Sintetica alle 9:00 EST a New York.
Inoltre, Foghorn presenterà alla TD Cowen 45th Annual Health Care Conference il 3 marzo 2025, alle 14:30 EST a Boston, con la direzione che condurrà anche incontri virtuali one-on-one quel giorno.
I webcast delle presentazioni saranno disponibili nella sezione
Foghorn Therapeutics (Nasdaq: FHTX), una empresa de biotecnología en etapa clínica centrada en corregir la expresión génica anormal, anunció su participación en dos próximas conferencias para inversores en febrero y marzo de 2025.
La empresa se unirá a la B. Riley Securities Precision Oncology and Radiopharma Conference el 28 de febrero de 2025, donde el presidente y CEO Adrian Gottschalk participará en un panel de Letalidad Sintética a las 9 a.m. EST en Nueva York.
Además, Foghorn presentará en la TD Cowen 45th Annual Health Care Conference el 3 de marzo de 2025, a las 2:30 p.m. EST en Boston, con la dirección también realizando reuniones virtuales uno a uno ese día.
Las transmisiones de las presentaciones estarán disponibles en la sección
포그혼 테라퓨틱스 (Nasdaq: FHTX)는 비정상적인 유전자 발현을 교정하는 데 초점을 맞춘 임상 단계의 생명공학 회사로, 2025년 2월과 3월에 열리는 두 개의 투자자 컨퍼런스에 참가한다고 발표했습니다.
회사는 2025년 2월 28일 B. Riley Securities Precision Oncology and Radiopharma Conference에 참석하며, 그 자리에서 CEO 아드리안 고트샬크가 뉴욕 EST 오전 9시에 합성 치사성 패널에 참여할 예정입니다.
또한, 포그혼은 2025년 3월 3일 보스턴에서 열리는 TD Cowen 45th Annual Health Care Conference에서 오후 2시 30분 EST에 발표하며, 경영진은 그날 가상 일대일 미팅도 진행할 예정입니다.
발표의 웹캐스트는 포그혼 웹사이트의
Foghorn Therapeutics (Nasdaq: FHTX), une société de biotechnologie en phase clinique axée sur la correction de l'expression génique anormale, a annoncé sa participation à deux conférences pour investisseurs prévues en février et mars 2025.
La société participera à la B. Riley Securities Precision Oncology and Radiopharma Conference le 28 février 2025, où le président et PDG Adrian Gottschalk participera à un panel sur la létalité synthétique à 9 h EST à New York.
De plus, Foghorn présentera à la TD Cowen 45th Annual Health Care Conference le 3 mars 2025, à 14 h 30 EST à Boston, avec la direction qui tiendra également des réunions virtuelles en tête-à-tête ce jour-là.
Les webcasts des présentations seront disponibles pendant 90 jours dans la section
Foghorn Therapeutics (Nasdaq: FHTX), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf die Korrektur abnormaler Genexpression konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im Februar und März 2025 bekannt gegeben.
Das Unternehmen wird am 28. Februar 2025 an der B. Riley Securities Precision Oncology and Radiopharma Conference teilnehmen, wo Präsident und CEO Adrian Gottschalk um 9 Uhr EST in New York an einem Panel zur synthetischen Letalität teilnehmen wird.
Darüber hinaus wird Foghorn am 3. März 2025 um 14:30 Uhr EST in Boston auf der TD Cowen 45th Annual Health Care Conference präsentieren, wobei das Management an diesem Tag auch virtuelle Einzelgespräche führen wird.
Webcasts der Präsentationen werden für 90 Tage im Abschnitt
- None.
- None.
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the B. Riley Securities Precision Oncology and Radiopharma Conference, and at the TD Cowen 45th Annual Health Care Conference. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
B. Riley Securities Precision Oncology and Radiopharma Conference
- Synthetic Lethality Panel: Friday, February 28, 2025, at 9 a.m. EST in New York, NY
- Presenter: Adrian Gottschalk, President and Chief Executive Officer
TD Cowen 45th Annual Health Care Conference
- Presentation: Monday, March 3, 2025, at 2:30 p.m. EST in Boston, MA
- Presenter: Adrian Gottschalk, President and Chief Executive Officer
- Please find a link to the webcast here
- Management will also participate in virtual one-on-one meetings on Monday, March 3, 2025
A webcast of the presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com, and will be available for 90 days.
About Foghorn Therapeutics
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X (formerly Twitter) and LinkedIn.
Contact:
Karin Hellsvik, Foghorn Therapeutics Inc.
khellsvik@foghorntx.com
FAQ
When will Foghorn Therapeutics (FHTX) present at the TD Cowen Health Care Conference in 2025?
What investor conferences is Foghorn Therapeutics (FHTX) attending in February-March 2025?
Who will represent Foghorn Therapeutics (FHTX) at the upcoming investor conferences?
Where can investors access the webcast of Foghorn Therapeutics' (FHTX) conference presentations?
What is the focus of Foghorn Therapeutics' (FHTX) Gene Traffic Control platform?
